Moxifloxacin Puren (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Puren, is a fluoroquinolone presented as an oral tablet for systemic use. It is indicated for the treatment of several bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, and other respiratory and skin infections in adult patients.

GNH USA supplies Moxifloxacin Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other health‑care institutions worldwide. Our distribution network adheres to stringent quality‑assurance standards, ensuring product integrity from manufacturing through delivery and timely support.

Moxifloxacin is a fluoroquinolone antibacterial used to treat infections caused by susceptible bacteria in various organ systems. - Community‑acquired bacterial pneumonia: effective therapy to achieve clinical cure and bacterial eradication. - Acute bacterial sinusitis: reduces symptoms and eliminates the causative pathogens. - Acute bacterial exacerbation of chronic bronchitis: shortens duration of illness and improves lung function. - Skin and skin structure infections: resolves infection and promotes healing of affected tissues. - Complicated intra‑abdominal infections: aids in bacterial clearance when used with appropriate surgical management.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea: mild gastrointestinal upset that may be transient. - Diarrhea: loose stools, usually self‑limited but can cause dehydration. - Headache: transient cranial discomfort, often resolves without treatment. - Dizziness: occasional vertigo or light‑headedness, especially on standing. - Rash: mild skin erythema or pruritus, typically non‑serious. Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur during or after therapy and requires immediate medical attention. - QT interval prolongation: can lead to cardiac arrhythmias such as torsades de pointes, particularly in patients with cardiac risk factors. - Severe hypersensitivity: includes anaphylaxis or Stevens‑Johnson syndrome, demanding urgent care. - Clostridioides difficile infection: colitis resulting from disruption of normal gut flora, presenting with severe diarrhea. - Hepatotoxicity: elevated liver enzymes or jaundice indicating possible liver injury.

When prescribing moxifloxacin, clinicians should consider several precautionary measures to minimize risks. - Assess renal and hepatic function: adjust therapy if significant impairment is present. - Review cardiac history: avoid in patients with known QT prolongation or arrhythmias. - Evaluate tendon risk: caution in elderly, those on corticosteroids, or with prior tendon disorders. - Monitor for hypersensitivity: discontinue at first sign of severe allergic reaction. - Use pregnancy and lactation caution: benefits must outweigh potential unknown risks. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of moxifloxacin. - Warfarin: may increase anticoagulant effect, raising bleeding risk. - Cyclosporine: can raise moxifloxacin plasma levels, increasing toxicity. Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of central nervous system stimulation. - Theophylline: potential for increased theophylline concentrations. - Oral contraceptives: may reduce contraceptive effectiveness.